Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06859268 · ClinicalTrials.gov registry record · Phase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

A Phase 3 study of Obesity, sponsored by Eli Lilly and Company.

Active
Registry status
Phase 3
Development phase
643
Enrollment target
20
Study locations

NCT06859268 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 643 participants, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (21% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06859268, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Eli Lilly and Company.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
643 participants
Enrollment target
20
Study locations

Study Summary

This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-blinded phase in which participants will either take retatrutide dose 1, retatrutide dose 2, or switch to placebo. Participation in the study will last around 125 weeks.

Conditions Studied

Obesity

Interventions

  • DRUG Placebo
  • DRUG Retatrutide

Study Locations (20)

Florida

  • ALL Medical Research, LLC - Cooper City
  • Florida International Medical Research - Coral Gables
  • Renstar Medical Research - Ocala
  • Charter Research - Winter Park - Orlando
  • Metabolic Research Institute, Inc. - West Palm Beach

Georgia

  • Kubost Clinical Research - Marietta - Marietta
  • North Georgia Clinical Research - Woodstock

Illinois

  • Alliance for Multispecialty Research, LLC - Oak Brook
  • Springfield Clinic Main Campus - Springfield

Kentucky

  • Alliance for Multispecialty Research, LLC - Lexington
  • L-MARC Research Center - Louisville

Louisiana

  • Pennington Biomedical Research Center - Baton Rouge
  • Care Access - Lake Charles (Bayou Pines) - Lake Charles

California

  • Southern California Clinical Research - Santa Ana

Colorado

  • University of Colorado Anschutz Medical Campus - Aurora

Connecticut

  • CMR of Greater New Haven, LLC - Hamden

Trial Details

FieldValue
Enrollment Target 643 participants
Start Date 2025-03-05
Est. Completion 2028-04
Phase Phase 3

Sponsor

Eli Lilly and Company

1,341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06859268

The ClinicalTrials.gov registry entry for NCT06859268 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 643 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 818-participant average among 1,053 other Obesity trials with a reported enrollment target (21% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06859268 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Georgia, Illinois.

Frequently Asked Questions

What is clinical trial NCT06859268 about?

NCT06859268 is a clinical study titled "A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity". This is a study of retatrutide in participants with obesity. The main purpose is to learn more about how retatrutide maintains body weight loss. The study will have two treatment phases: an 80 week lead-in phase in which all participants will take retatrutide dose 1 and a 36 week randomized, double-...

What is the current status of trial NCT06859268?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 643 participants. The study started on 2025-03-05. Estimated completion is 2028-04.

What conditions does trial NCT06859268 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT06859268?

The interventions under investigation include: Placebo (DRUG), Retatrutide (DRUG).

Who is sponsoring clinical trial NCT06859268?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06859268 being conducted?

This trial has 20 study locations across California, Colorado, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.